⏳ One week out — see why leaders are heading to the 2025 STAT Summit

2025BSW_LC_Marketing_EmailTall_1WeekAway (1)

Last chance to join 400+ biotech, pharma, and science leaders in Boston

Next week, the 2025 STAT Summit will bring together a highly curated group of leaders across health and medicine, with every in-person attendee selected or approved by STAT's editorial events team.

More than half of those joining us are VP level and above, and over 20% are scientists, physicians, and researchers — creating a rare mix of strategic and scientific voices from across biotech, pharma, investment, and policy. Don't miss your chance to be in the room.

JOIN US LIVE IN BOSTON

Across two days, the conversations on stage will confront the questions driving the next decade of innovation:

How far can CRISPR go? Hear from Baby KJ's family and the researchers behind a groundbreaking gene-editing success that could redefine what's possible in medicine — with STAT's Jason Mast.
How will pharma adapt? Emma Walmsley of GSK, Christopher Viehbacher of Biogen, and John Maraganore, founding CEO of Alnylam Pharmaceuticals, join STAT's Matthew Herper to look ahead at the forces reshaping global drug development.
Can biotech navigate regulatory uncertainty? CEOs join STAT's Adam Feuerstein to discuss what recent FDA decisions reveal about risk, timing, and the path to approval.
What does China's rise mean for biotech? STAT's Allison DeAngelis sits down with Michelle Xia of Akeso Biopharma to explore how China's fast-rising biotech sector is changing the landscape for innovation and investment.
How do we strengthen the foundation of care? STAT's Chelsea Cirruzzo speaks with AMA President Bobby Mukkamala, who draws on his experience as a Flint physician and cancer survivor to discuss access, burnout, and sweeping federal cuts.

Plus conversations on the evolving federal landscape, the state of public health, biotech financing, tackling medical misinformation, health tech breakthroughs, and more.

We hope to see you there!